Search clinical trials for: anti-CD19 allo-CAR-T cells

Total 7399 results

RenJi Hospital

Unknown

CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR

Advanced Glioma

China
Kang YU
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Hepatocellular Carcinoma | B Cell Lymphoma | Pancreatic Carcinoma | Myeloma | B Cell Leukemia | Adenocarcinoma of Esophagogastric Junction

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Lymphocytic Leukemia

United States
Shenzhen University General Hospital

Recruiting

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma (CAR-T)

Non-hodgkin Lymphoma,B Cell

China
RenJi Hospital

Completed

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Hepatocellular Carcinoma

China
Cellular Biomedicine Group Ltd.
Shanghai Tongji Hospital, Tongji University School of Medicine

Unknown

Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

Refractory or Relapsed Non-Hodgkin Lymphoma

China
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
Institute of Hematology & Blood Diseases Hospital...
Suzhou Fundamenta Therapeutics

Recruiting

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Autoimmune Hemolytic Anemia | CD19 CAR-T Cell Infusion

China
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Shanghai Longyao Biotechnology Inc., Ltd.
Xuzhou Medical University; Shanghai Jiao Tong University School of Medicine

Unknown

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

Recurrent or Refractory B Cell Malignancy

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Completed

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Transformed Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

China
Bioray Laboratories
Wuhan Union Hospital, China; Zhejiang University; Institute of Hematology ＆ Blood...

Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Xuzhou Medical University

Recruiting

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Shanghai GeneChem Co., Ltd.
Shanghai Cancer Hospital, China

Unknown

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Carcinoma, Hepatocellular | Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Changhai Hospital
UTC Therapeutics Inc.

Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

CD70-positive Advanced Urologic Neoplasms

China
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
Minerva Biotechnologies Corporation
City of Hope Medical Center

Recruiting

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

Metastatic Breast Cancer

United States
Dr. Melody Smith, MD, MS
Orca Biosystems, Inc.

Recruiting

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Lymphoid Leukemia

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Southwest Hospital, China

Recruiting

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Lymphoma | Leukemia

China
Seattle Children's Hospital

Active, not recruiting

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

CD19+ Acute Leukemia

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

Autoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still Disease

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Tongji Hospital

Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

19 and 22+ B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic Tumors

China
OneChain Immunotherapeutics
Hospital Clinic of Barcelona; Hospital Sant Joan de Deu; BioClever 2005 S.L.

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)

T-cell Acute Lymphoblastic Leukemia | Lymphoblastic T-Cell Lymphoma

Spain
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

Melanoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

China
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma

China
Seoul National University Hospital

Recruiting

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Very High Risk Acute Lymphoblastic Leukemia | CD19 CAR-T Therapy

Korea, Republic of
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Jiujiang University Affiliated Hospital
KAEDI

Withdrawn

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Wuhan Union Hospital, China

Not yet recruiting

CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Search clinical trials for: anti-CD19 allo-CAR-T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations